Key result
PCSK9 inhibitors reduce ASCVD events in high-risk patients while lowering LDL-C by ~60%.
Why the study?
PCSK9 inhibitors have shown significant LDL-C lowering and cardiovascular event reduction in high-risk patients, but evolving evidence on their use and safety profile requires synthesis.
Do PCSK9 inhibitors reduce LDL-C and atherosclerotic cardiovascular disease events in high-risk patients?
Do PCSK9 inhibitors reduce LDL-C and atherosclerotic cardiovascular disease events in high-risk patients?
PCSK9 inhibitors provide profound LDL-C lowering (55-72%) and reduce ASCVD events in high-risk patients, supporting the concept that there is no lower limit for LDL-C.
Supports aggressive lipid lowering for high-risk patients on maximal therapy; extends evidence that.
Variants in proprotein convertase subtilisin/kexin type 9 (PCSK9) provide insights into mechanisms regulating low-density lipoprotein (LDL) levels. Human monoclonal antibodies that target PCSK9 lower LDL cholesterol (LDL-C) levels by 55% to 72% in different high-risk patient groups. Clinical trials with PCSK9 inhibitors have demonstrated reductions in atherosclerotic cardiovascular disease events, particularly in patients with recent acute coronary syndrome, multivessel coronary artery disease, or peripheral arterial disease. Commonly observed profound reductions in LDL-C to levels <25 mg/dl have been accompanied by even lower rates of atherosclerotic cardiovascular disease events, thus supporting the concept that there may be no lower limit for LDL-C. Aggressive LDL-C lowering with fully human PCSK9 monoclonal antibodies has been accompanied by a safety profile that has been very favorable. On the basis of clinical trial evidence, LDL lowering with PCSK9 inhibitors is recommended for high-risk patients with LDL-C levels ≥70 mg/dl on maximally tolerated oral therapies including statins and/or ezetimibe.
No takes yet. Share an insight, caveat, or question.
Rosenson et al. (2018) conducted a review in High cardiovascular risk with elevated LDL cholesterol. PCSK9 inhibitors was evaluated on LDL cholesterol levels and atherosclerotic cardiovascular disease events. PCSK9 inhibitors lower LDL cholesterol levels by 55% to 72% and reduce atherosclerotic cardiovascular disease events in high-risk patients.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: